These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. Ripping TM; Witjes JA; Meijer RP; van Rhijn BWG; Oddens JR; Goossens-Laan CA; Mulder SF; van Moorselaar RJA; Kiemeney LA; Aben KKH Urol Oncol; 2020 Dec; 38(12):935.e9-935.e16. PubMed ID: 32917503 [TBL] [Abstract][Full Text] [Related]
6. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis. Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102 [TBL] [Abstract][Full Text] [Related]
7. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841 [TBL] [Abstract][Full Text] [Related]
8. Hospital volume and perioperative outcomes for radical cystectomy: a population study. Udovicich C; Perera M; Huq M; Wong LM; Lenaghan D BJU Int; 2017 May; 119 Suppl 5():26-32. PubMed ID: 28544301 [TBL] [Abstract][Full Text] [Related]
10. Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': the case for super centralisation. Afshar M; Goodfellow H; Jackson-Spence F; Evison F; Parkin J; Bryan RT; Parsons H; James ND; Patel P BJU Int; 2018 Feb; 121(2):217-224. PubMed ID: 28594471 [TBL] [Abstract][Full Text] [Related]
11. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162 [TBL] [Abstract][Full Text] [Related]
12. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. Ritch CR; Balise R; Prakash NS; Alonzo D; Almengo K; Alameddine M; Venkatramani V; Punnen S; Parekh DJ; Gonzalgo ML BJU Int; 2018 May; 121(5):745-751. PubMed ID: 29281848 [TBL] [Abstract][Full Text] [Related]
13. Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Vetterlein MW; Meyer CP; Leyh-Bannurah SR; Mayr R; Gierth M; Fritsche HM; Burger M; Keck B; Wullich B; Martini T; Bolenz C; Pycha A; Hanske J; Roghmann F; Noldus J; Bastian PJ; Gilfrich C; May M; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A; Clin Genitourin Cancer; 2017 Oct; 15(5):e809-e817. PubMed ID: 28550955 [TBL] [Abstract][Full Text] [Related]
14. The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. Bruins HM; Veskimäe E; Hernández V; Neuzillet Y; Cathomas R; Compérat EM; Cowan NC; Gakis G; Espinós EL; Lorch A; Ribal MJ; Rouanne M; Thalmann GN; Yuan Y; der Heijden AGV; Witjes JA Eur Urol Oncol; 2020 Apr; 3(2):131-144. PubMed ID: 31866215 [TBL] [Abstract][Full Text] [Related]
15. Hospital Quality Metrics for Radical Cystectomy: Disease Specific and Correlated to Mortality Outcomes. Khanna A; Saarela O; Lawson K; Finelli A; Haber GP; Lee B; Abouassaly R J Urol; 2019 Sep; 202(3):490-497. PubMed ID: 31009290 [TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate. Goossens-Laan CA; Gooiker GA; van Gijn W; Post PN; Bosch JL; Kil PJ; Wouters MW Eur Urol; 2011 May; 59(5):775-83. PubMed ID: 21310525 [TBL] [Abstract][Full Text] [Related]
17. Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. Porter MP; Gore JL; Wright JL World J Urol; 2011 Feb; 29(1):73-7. PubMed ID: 21132553 [TBL] [Abstract][Full Text] [Related]
18. Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. Leow JJ; Reese S; Trinh QD; Bellmunt J; Chung BI; Kibel AS; Chang SL BJU Int; 2015 May; 115(5):713-21. PubMed ID: 24674655 [TBL] [Abstract][Full Text] [Related]
19. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU; Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383 [TBL] [Abstract][Full Text] [Related]
20. Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). Häggström C; Liedberg F; Hagberg O; Aljabery F; Ströck V; Hosseini A; Gårdmark T; Sherif A; Malmström PU; Garmo H; Jahnson S; Holmberg L BMJ Open; 2017 Sep; 7(9):e016606. PubMed ID: 28963292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]